Press Releases

Date Title and Summary Additional Formats
Toggle Summary AMICUS THERAPEUTICS FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR AT2101 FOR GAUCHER DISEASE
Phase I Clinical Trials Expected to Commence in June
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR AT2101 FOR GAUCHER DISEASE
Phase I Clinical Trials Expected to Commence in June
View HTML
Toggle Summary EUROPEAN REGULATORY COMMITTEE RECOMMENDS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR AMICUS THERAPEUTICS' AMIGAL™ FOR FABRY DISEASE
EUROPEAN REGULATORY COMMITTEE RECOMMENDS ORPHAN MEDICINAL PRODUCT DESIGNATION FOR AMICUS THERAPEUTICS' AMIGAL™ FOR FABRY DISEASE Cranbury, NJ, April 11, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS PHARMACEUTICAL VETERAN DONALD HAYDEN, JR. EXECUTIVE CHAIRMAN OF ITS BOARD OF DIRECTORS
AMICUS THERAPEUTICS APPOINTS PHARMACEUTICAL VETERAN DONALD HAYDEN, JR. EXECUTIVE CHAIRMAN OF ITS BOARD OF DIRECTORS Cranbury, NJ, March 31, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human
View HTML
Toggle Summary AMICUS THERAPEUTICS' AT2101 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF GAUCHER DISEASE
AMICUS THERAPEUTICS' AT2101 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF GAUCHER DISEASE Cranbury, NJ, February 15, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS DAVID J. LOCKHART CHIEF SCIENTIFIC OFFICER
Dr. Lockhart Will Lead the Research Organization and Oversee the Advancement of Amicus' Pharmacological Chaperone Technology
View HTML
Toggle Summary AMICUS THERAPEUTICS TO PRESENT AT JPMORGAN HEALTHCARE CONFERENCE
AMICUS THERAPEUTICS TO PRESENT AT JPMORGAN HEALTHCARE CONFERENCE Cranbury, NJ, January 4, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that the company will
View HTML
Toggle Summary PHASE I CLINICAL STUDIES DEMONSTRATE SAFETY AND INITIAL "PROOF OF CONCEPT" FOR AMICUS' FABRY DISEASE DRUG
Lead Compound Based on Unique Pharmacological Chaperone Technology to Correct Misfolded Proteins Demonstrates Positive Biological Activity in Healthy Volunteers <br /><br />Amicus Initiates Phase II Clinical Program
View HTML
Toggle Summary AMICUS THERAPEUTICS RAISES $55 MILLION SERIES C FINANCING
New Funds to Accelerate Development of Unique Pharmacological Chaperones to Correct Misfolded Proteins <br /><br /> Pipeline Has the Potential to Transform Treatment of Human Genetic Diseases
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS JOHN F. CROWLEY CHAIRMAN AND CEO
New Executives Named to Management Team
View HTML